Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 68 |
| Active Pipeline (Recruiting Now) | 21 (17) |
| Completed vs Stopped Early | 33 / 14 (20.6%) |
| Median Closed Actual Enrollment | 83 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Minnesota | Minneapolis, MN | 50 |
| UT Southwestern Simmons Cancer Center | Dallas, TX | 4 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05605093 | Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir) | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the University of Minnesota Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.